“…Clozapine is the atypical APD, which does not appear to have EPS liability and targets negative as well as positive symptoms (for review, see Deutch et al, 1991 b). Remoxipride, a new putative APD that binds to D 2 DA receptors and the sigma site (Ogren etal., 1984(Ogren etal., , 1990, is a therapeutically effective agent (Ahlfors et al, 1990;Pflug et al, 1990;Lewander et al, 1990), that has very low EPS liability (Walinder and Holm, 1990); two controlled comparison studies have indicated that remoxipride has less or comparable EPS liability than thioridazine (McReadie et al, 1990;Phanjoo and Link, 1990). Preliminary data suggest that remoxipride may target negative as well as positive symptoms (Lewander etal., 1990), but this suggestion awaits confirmation.…”